Stocktoria
Tarsus Pharmaceuticals, Inc. TARS
Tarsus Pharmaceuticals, Inc. (TARS) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $451.4M at a -14.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-04 | HC Wainwright & Co. | Buy (reit) |
| 2026-02-25 | Oppenheimer | Outperform (main) |
| 2026-02-25 | Guggenheim | Buy (main) |
| 2025-12-09 | Barclays | Overweight (init) |
| 2025-11-20 | Mizuho | Outperform (init) |
| 2025-11-05 | Guggenheim | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.689 |
| Retained earnings / assets | -0.759 |
| EBIT / assets | -0.126 |
| Equity / liabilities | 1.57 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TARS | Tarsus Pharmaceuticals, Inc. | 4/9 | 2.84 | — | +146.7% |
| IMCR | Immunocore Holdings plc | 3/9 | 2.37 | — | +29% |
| ADMA | ADMA BIOLOGICS, INC. | 5/9 | 8.8 | 13.8 | +19.6% |
| KRYS | Krystal Biotech, Inc. | 5/9 | 16.61 | 53.6 | +33.9% |
| TWST | Twist Bioscience Corp | 3/9 | -2.72 | — | +20.3% |
| VCEL | Vericel Corp | 7/9 | 3.1 | 118.9 | +16.5% |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | 2/9 | -7.27 | — | +60.6% |
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
FAQ
Is TARS financially healthy?
Tarsus Pharmaceuticals, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does TARS pay a dividend?
No, Tarsus Pharmaceuticals, Inc. does not currently pay a dividend.
How profitable is TARS?
In FY2025, Tarsus Pharmaceuticals, Inc. had a net margin of -14.7% and a return on equity of -19.3%.
What is the analyst price target for TARS?
The average Wall-Street price target for Tarsus Pharmaceuticals, Inc. is $94.11, about 34.4% above the recent price, from 9 analysts.
Is TARS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Tarsus Pharmaceuticals, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.